Purpose of reviewSARS-CoV2 is a β-coronavirus, isolated for the first time in Wuhan in December 2019. Bilateral interstitial pneumonia is the hallmark of this disease. Liver is the second viral target for frequency and AST and ALT elevation is a common finding. From February 2020, two different cholangiopathies have been reported in COVID-19 patients. The aim of this article is to review the cases so far described in order to share information and awareness about these new clinical entities.Recent findingsSARS-CoV2 seems to trigger autoimmunity and two cases of primary biliary cholangitis (PBC) have been developed after viral infection while more than 30 patients have showed a rapidly progressing cholangiopathy with features of secondary sclerosing cholangitis (SSC). For what concerns SSC pathogenesis, a theory combining multiple hits is the most recognized.SummaryTwo different cholangiopathies have been reported in patients after severe-COVID-19. Attention should be paid to the development of cholestasis in ICU setting but above all after discharge and liver function tests should be, therefore, periodically performed. No treatment strategies are available and liver transplantation remains the last option in individuals with liver failure because of SSC. Other efforts are necessary to better understand the pathogenesis and to expand therapeutic options.

Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies / Bartoli, A.; Cursaro, C.; Andreone, P.. - In: CURRENT OPINION IN GASTROENTEROLOGY. - ISSN 0267-1379. - 38:2(2022), pp. 89-97. [10.1097/MOG.0000000000000808]

Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies

Bartoli A.;Cursaro C.;Andreone P.
2022

Abstract

Purpose of reviewSARS-CoV2 is a β-coronavirus, isolated for the first time in Wuhan in December 2019. Bilateral interstitial pneumonia is the hallmark of this disease. Liver is the second viral target for frequency and AST and ALT elevation is a common finding. From February 2020, two different cholangiopathies have been reported in COVID-19 patients. The aim of this article is to review the cases so far described in order to share information and awareness about these new clinical entities.Recent findingsSARS-CoV2 seems to trigger autoimmunity and two cases of primary biliary cholangitis (PBC) have been developed after viral infection while more than 30 patients have showed a rapidly progressing cholangiopathy with features of secondary sclerosing cholangitis (SSC). For what concerns SSC pathogenesis, a theory combining multiple hits is the most recognized.SummaryTwo different cholangiopathies have been reported in patients after severe-COVID-19. Attention should be paid to the development of cholestasis in ICU setting but above all after discharge and liver function tests should be, therefore, periodically performed. No treatment strategies are available and liver transplantation remains the last option in individuals with liver failure because of SSC. Other efforts are necessary to better understand the pathogenesis and to expand therapeutic options.
38
2
89
97
Severe acute respiratory syndrome coronavirus-2-associated cholangiopathies / Bartoli, A.; Cursaro, C.; Andreone, P.. - In: CURRENT OPINION IN GASTROENTEROLOGY. - ISSN 0267-1379. - 38:2(2022), pp. 89-97. [10.1097/MOG.0000000000000808]
Bartoli, A.; Cursaro, C.; Andreone, P.
File in questo prodotto:
File Dimensione Formato  
Severe_acute_respiratory_syndrome.4.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 291.8 kB
Formato Adobe PDF
291.8 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1281251
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact